JSF Financial LLC Invests $894,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

JSF Financial LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,993 shares of the medical equipment provider's stock, valued at approximately $894,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $1,066,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $25,955,000. Van ECK Associates Corp increased its stake in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after purchasing an additional 21,604 shares during the last quarter. Finally, Empirical Asset Management LLC purchased a new stake in shares of Lantheus during the 4th quarter worth approximately $323,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

NASDAQ:LNTH traded down $1.61 during trading hours on Friday, hitting $80.35. The stock had a trading volume of 385,227 shares, compared to its average volume of 778,160. The company has a 50 day simple moving average of $91.76 and a two-hundred day simple moving average of $98.13. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of 13.37 and a beta of 0.44.

Remove Ads

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on LNTH. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. Truist Financial reiterated a "buy" rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.